NasdaqCM - Delayed Quote USD

Aytu BioPharma, Inc. (AYTU)

2.9043 +0.1243 (+4.47%)
At close: April 26 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Total Revenue
98,498.0000
107,399.0000
96,669.0000
65,632.0000
27,632.0000
Cost of Revenue
36,204.0000
40,767.0000
44,386.0000
36,432.0000
8,281.0000
Gross Profit
62,294.0000
66,632.0000
52,283.0000
29,200.0000
19,351.0000
Operating Expense
67,917.0000
78,961.0000
88,386.0000
67,440.0000
37,272.0000
Operating Income
-5,623.0000
-12,329.0000
-36,103.0000
-38,240.0000
-17,921.0000
Other Income Expense
-11,546.0000
-4,722.0000
-72,786.0000
-19,790.0000
4,300.0000
Pretax Income
-17,169.0000
-17,051.0000
-108,889.0000
-58,030.0000
-13,621.0000
Tax Provision
828.0000
--
-110.0000
259.0000
--
Net Income Common Stockholders
-17,997.0000
-17,051.0000
-108,779.0000
-58,289.0000
-13,621.0000
Diluted NI Available to Com Stockholders
-17,997.0000
-17,051.0000
-108,779.0000
-58,289.0000
-13,621.0000
Basic EPS
-4.01
-5.11
-74.01
-69.60
-60.00
Diluted EPS
-4.01
-5.11
-74.01
-69.60
-60.00
Basic Average Shares
4,680.8920
3,339.9060
1,469.8750
837.3330
225.9600
Diluted Average Shares
4,680.8920
3,339.9060
1,469.8750
837.3330
225.9600
Total Operating Income as Reported
-7,529.0000
-17,065.0000
-109,906.0000
-58,870.0000
-21,131.0000
Total Expenses
104,121.0000
119,728.0000
132,772.0000
103,872.0000
45,553.0000
Net Income from Continuing & Discontinued Operation
-17,997.0000
-17,051.0000
-108,779.0000
-58,289.0000
-13,621.0000
Normalized Income
-12,316.1100
-17,108.0000
-36,814.8261
-40,628.8300
-20,527.0000
EBIT
-5,623.0000
-12,329.0000
-36,103.0000
-38,240.0000
-17,921.0000
EBITDA
3,094.0000
-3,514.0000
-25,957.0000
-29,039.0000
-12,207.0000
Reconciled Cost of Revenue
32,486.0000
36,740.0000
40,084.0000
33,240.0000
7,057.0000
Reconciled Depreciation
8,717.0000
8,815.0000
10,146.0000
9,201.0000
5,714.0000
Net Income from Continuing Operation Net Minority Interest
-17,997.0000
-17,051.0000
-108,779.0000
-58,289.0000
-13,621.0000
Total Unusual Items Excluding Goodwill
-7,191.0000
57.0000
-72,029.0000
-17,740.0000
6,906.0000
Total Unusual Items
-7,191.0000
57.0000
-72,029.0000
-17,740.0000
6,906.0000
Normalized EBITDA
10,285.0000
-3,571.0000
46,072.0000
-11,299.0000
-19,113.0000
Tax Rate for Calcs
0.0002
--
0.0000
0.0000
--
Tax Effect of Unusual Items
-1,510.1100
--
-64.8261
-79.8300
--
6/30/2020 - 9/25/2008

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MEDXF Medexus Pharmaceuticals Inc.
1.3850
+2.59%
 
AGRX Agile Therapeutics, Inc.
0.4000
0.00%
 
BFRI Biofrontera Inc.
1.5900
-7.02%
 
DRRX DURECT Corporation
0.9313
+1.68%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.3850
-0.90%
 
GHSI Guardion Health Sciences, Inc.
7.90
-2.83%
 
CLVR Clever Leaves Holdings Inc.
4.1100
+0.98%
 
HUGE FSD Pharma Inc.
0.4799
+1.24%
 
DERM Journey Medical Corporation
3.4000
-2.86%
 
CYTH Cyclo Therapeutics, Inc.
1.2600
-5.26%